RNXT
Price
$1.16
Change
+$0.02 (+1.75%)
Updated
Oct 19 closing price
Capitalization
52.35M
27 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.61
Change
+$0.15 (+4.34%)
Updated
Oct 19 closing price
Capitalization
1.94B
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RNXT vs RXRX

RNXT vs RXRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RNXT vs. RXRX commentary
Oct 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNXT is a Hold and RXRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RNXT with price predictions
Oct 19, 2026

Momentum Indicator for RNXT turns negative, indicating new downward trend

RNXT saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 86 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

RNXT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RNXT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for RNXT entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNXT's RSI Oscillator exited the oversold zone, 32 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

RNXT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.830) is normal, around the industry mean (2.978). P/E Ratio (-3.742) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (31.250) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RXRX with price predictions
Oct 19, 2026

RXRX in downward trend: price dove below 50-day moving average on October 16, 2026

RXRX moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend. In 49 of 54 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 80 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 206 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 110 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.116) is normal, around the industry mean (2.978). P/E Ratio (-3.610) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
RNXTRXRX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 15 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
COMPARISON
Comparison
Oct 20, 2026
Stock price -- (RNXT: $1.16 vs. RXRX: $3.61)
Brand notoriety: RNXT and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNXT: 36% vs. RXRX: 119%
Market capitalization -- RNXT: $52.35M vs. RXRX: $1.94B
RNXT [@Biotechnology] is valued at $52.35M. RXRX’s [@Biotechnology] market capitalization is $1.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $127.22B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNXT’s FA Score shows that 0 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).

  • RNXT’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than RNXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNXT’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • RNXT’s TA Score: 3 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both RNXT and RXRX are a bad buy in the short-term.

Price Growth

RNXT (@Biotechnology) experienced а -7.20% price change this week, while RXRX (@Biotechnology) price change was -9.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.

Reported Earning Dates

RNXT is expected to report earnings on Nov 16, 2026.

RXRX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-7.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RNXT
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CELH29.721.53
+5.43%
Celsius Holdings
DSGR35.05-0.01
-0.03%
Distribution Solutions Group
VSDB74.71-0.05
-0.07%
Vanguard Short Duration Bond ETF (VSDB)
AVBH30.78-0.15
-0.48%
Avidbank Holdings Inc
CATO2.31-0.04
-1.70%
CATO Corp

RNXT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNXT has been loosely correlated with RXRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if RNXT jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNXT
1D Price
Change %
RNXT100%
+1.75%
RXRX - RNXT
33%
Loosely correlated
+4.18%
RCKT - RNXT
31%
Poorly correlated
+2.75%
AVXL - RNXT
29%
Poorly correlated
-4.58%
SPRB - RNXT
29%
Poorly correlated
+1.89%
PRME - RNXT
27%
Poorly correlated
+10.37%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+4.18%
CRSP - RXRX
64%
Loosely correlated
+1.60%
PRME - RXRX
62%
Loosely correlated
+10.37%
ABSI - RXRX
62%
Loosely correlated
+3.52%
BEAM - RXRX
59%
Loosely correlated
+3.07%
ABCL - RXRX
57%
Loosely correlated
+1.10%
More